GENV HEM
Alternative Names: AAV8.FVa; GENV-HEMLatest Information Update: 19 Apr 2024
At a glance
- Originator University of North Carolina
- Developer GeneVentiv Therapeutics
- Class Antihaemorrhagics; Gene therapies
- Mechanism of Action Factor V replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haemophilia
Most Recent Events
- 16 Apr 2024 GeneVentiv Therapeutics receives SBIR grant from the National Heart Lung Blood Institute (NHLBI) for GENV-HEM development in Haemophilia
- 13 Mar 2024 GeneVentiv announces intention to submit IND application to the US FDA for hemophilia
- 13 Mar 2024 GeneVentiv plans a phase I/II trial for Haemophilia